Imedex® is an industry leader in providing certified, independent continuing medical education to health care professionals.

April 1, 2016

New York, New York
Wyndham New Yorker Hotel

Individualizing Late-Line Treatment for Patients with Metastatic Colorectal Cancer

A Luncheon Symposium at Great Debates and Updates in GI Malignancies


April 1, 2016
12:40 pm – 2:10 pm
Crystal Ballroom, Wyndham New Yorker Hotel
481 8th Avenue & 34th Street
New York City, New York 10001
ph. 1-800-764-4680
http://www.newyorkerhotel.com/

Faculty

Axel Grothey, MD
Mayo Clinic College of Medicine 
Rochester, Minnesota

Howard Hochster, MD
Yale School of Medicine
New Haven, Connecticut

Eric Van Cutsem, MD, PhD
University Hospital Leuven
Clinical Digestive Oncology 
Leuven, Belgium

Scientific Agenda

Friday, April 1, 2016

12:40 pm

Lunch

1:00 pm

Welcome and introduction by moderator
Axel Grothey, MD

1:05 pm

Pre-activity survey
Axel Grothey, MD

1:10 pm

Emerging treatment options for patients in the late-line setting
Eric Van Cutsem, MD, PhD

1:25 pm

Management of adverse events associated with third-line treatments
Howard Hochster, MD

1:40 pm

Expert panel discussion: Integrating new treatments into clinical practice
Moderator: Axel Grothey, MD
Panel: Howard Hochster, MD and Eric Van Cutsem, MD, PhD

1:55 pm

Post-activity survey
Axel Grothey, MD

2:00 pm

Symposium adjourns

 

Continuing Medical Education

Imedex®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex®, LLC designates this live educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Who Should Attend

The proposed activities are designed to meet the educational needs of community oncologists, GI surgeons, GI internists, and other healthcare professionals (physicians, physicians-in-training, oncology nurses, nurse practitioners, pharmacists, physicians' assistants, etc.) involved and/or interested in the therapeutic management of patients with metastatic CRC.

Objectives

Upon completion of these educational activities, participants should be better able to:

  • Evaluate and plan to integrate emerging third-line treatment strategies into clinical practice for patients with metastatic CRC
  • Plan strategies to effectively manage common adverse events associated with third-line CRC treatments

Support

The following company has provided an educational grant in support of this symposium:
Bayer HealthCare Pharmaceuticals, Inc.

Registration

The Individualizing Late-Line Treatment for Patients with Metastatic Colorectal Cancer symposium will be presented at the Great Debates and Updates in GI Malignances meeting and is open to attendees registered for that meeting.  To register for Great Debates and Update in GI Malignancies please follow this link: http://imedex.com/gi-malignancies-debate-conference/registration.asp. There is no additional fee to attend the symposium and pre-registration for the symposium is not required.

Organizer

Imedex
11675 Rainwater Drive, Suite 600
Alpharetta, GA 30009, USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Email: meetings@imedex.com
Twitter: twitter.com/ImedexCME
Facebook: facebook.com/Imedex
Web: www.imedex.com